Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES)

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES)

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Go back to Resources

Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Authors:

Location:

Go back to Resources

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Go back to Resources

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Horizontal rectus tenotomy in patients with congenital nystagmus (CN): results in ten adults

Go back to Resources

Horizontal rectus tenotomy in patients with congenital nystagmus (CN): results in ten adults

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results from the Inaugural Year of the Collaborative Islet Transplant Registry (CITR)

Go back to Resources

Results from the Inaugural Year of the Collaborative Islet Transplant Registry (CITR)

Authors:

Location:

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease

Authors:

Location:

Go back to Resources

Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection

Go back to Resources

Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection

Authors:

Location:

Go back to Resources

Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival

Go back to Resources

Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 145
  • Page 146
  • Page 147
  • Page 148
  • Current page 149
  • Page 150
  • Page 151
  • Page 152
  • Page 153
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification